3p0q
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='3p0q' size='340' side='right'caption='[[3p0q]], [[Resolution|resolution]] 1.90Å' scene=''> | <StructureSection load='3p0q' size='340' side='right'caption='[[3p0q]], [[Resolution|resolution]] 1.90Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[3p0q]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/ | + | <table><tr><td colspan='2'>[[3p0q]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3P0Q OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3P0Q FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NNL:N-[2-(4-CHLOROPHENYL)ETHYL]-6-METHYL[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-8-AMINE'>NNL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9Å</td></tr> |
- | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NNL:N-[2-(4-CHLOROPHENYL)ETHYL]-6-METHYL[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-8-AMINE'>NNL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |
- | + | ||
- | + | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3p0q FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3p0q OCA], [https://pdbe.org/3p0q PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3p0q RCSB], [https://www.ebi.ac.uk/pdbsum/3p0q PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3p0q ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3p0q FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3p0q OCA], [https://pdbe.org/3p0q PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3p0q RCSB], [https://www.ebi.ac.uk/pdbsum/3p0q PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3p0q ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
- | + | [https://www.uniprot.org/uniprot/TNKS2_HUMAN TNKS2_HUMAN] Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles.<ref>PMID:11802774</ref> <ref>PMID:11739745</ref> <ref>PMID:19759537</ref> <ref>PMID:21478859</ref> | |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 28: | Line 26: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Homo sapiens]] |
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: Arrowsmith | + | [[Category: Arrowsmith CH]] |
- | + | [[Category: Berglund H]] | |
- | [[Category: Berglund | + | [[Category: Bountra C]] |
- | [[Category: Bountra | + | [[Category: Collins R]] |
- | [[Category: Collins | + | [[Category: Edwards AM]] |
- | [[Category: Edwards | + | [[Category: Flodin S]] |
- | [[Category: Flodin | + | [[Category: Flores A]] |
- | [[Category: Flores | + | [[Category: Graslund S]] |
- | [[Category: Graslund | + | [[Category: Hammarstrom M]] |
- | [[Category: Hammarstrom | + | [[Category: Johansson I]] |
- | [[Category: Johansson | + | [[Category: Karlberg T]] |
- | [[Category: Karlberg | + | [[Category: Kotenyova T]] |
- | [[Category: Kotenyova | + | [[Category: Kouznetsova E]] |
- | [[Category: Kouznetsova | + | [[Category: Moche M]] |
- | [[Category: Moche | + | [[Category: Nordlund P]] |
- | [[Category: Nordlund | + | [[Category: Nyman T]] |
- | [[Category: Nyman | + | [[Category: Persson C]] |
- | [[Category: Persson | + | [[Category: Schuler H]] |
- | + | [[Category: Schutz P]] | |
- | [[Category: Schuler | + | [[Category: Sehic A]] |
- | [[Category: Schutz | + | [[Category: Siponen MI]] |
- | [[Category: Sehic | + | [[Category: Thorsell AG]] |
- | [[Category: Siponen | + | [[Category: Tresaugues L]] |
- | [[Category: Thorsell | + | [[Category: Van Den Berg S]] |
- | [[Category: Tresaugues | + | [[Category: Wahlberg E]] |
- | [[Category: | + | [[Category: Weigelt J]] |
- | [[Category: | + | [[Category: Welin M]] |
- | [[Category: | + | |
- | [[Category: | + | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + |
Current revision
Human Tankyrase 2 - Catalytic PARP domain in complex with an inhibitor
|
Categories: Homo sapiens | Large Structures | Arrowsmith CH | Berglund H | Bountra C | Collins R | Edwards AM | Flodin S | Flores A | Graslund S | Hammarstrom M | Johansson I | Karlberg T | Kotenyova T | Kouznetsova E | Moche M | Nordlund P | Nyman T | Persson C | Schuler H | Schutz P | Sehic A | Siponen MI | Thorsell AG | Tresaugues L | Van Den Berg S | Wahlberg E | Weigelt J | Welin M